Report name (year)	Intention of the study	Technology Name	Tech. time frame	Purpose of the technology	Specialty	Technology type
BT Calendar 1997	Commercial	Artificial muscle use in place of heart transplants	1	Treatment and management of symptoms and disease	IX - circulation	Regenerative medicine
BT Calendar 1997	Commercial	Telemed link to home with home blood test kit	1	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth
BT Calendar 1997	Commercial	Artificial intelligence based elderly and handicapped support devices	1	Rehabilitation	XXI - screening, rehab	Assistive devices
BT Calendar 1997	Commercial	Artificial pancreas	1	Treatment and management of symptoms and disease	XI - GI tract, dental health	Regenerative medicine
BT Calendar 1997	Commercial	Artificial blood	3	Treatment and management of symptoms and disease	III - blood	Regenerative medicine
BT Calendar 1997	Commercial	Disability assistance devices using thought recognition	3	Rehabilitation	XXI - screening, rehab	Assistive devices
BT Calendar 1997	Commercial	Artificial ears	3	Rehabilitation	VIII - ear	Regenerative medicine
BT Calendar 1997	Commercial	Electronic implants used to stimulate muscles in disabled people	5	Rehabilitation	XIII - musculoske letal	Devices and biomaterials
BT Calendar 1997	Commercial	Home (health) diagnostic systems, daily/real time check-up	1	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth
BT Calendar 1997	Commercial	Virtual Reality based exercisers in homes	1	Health promotion and prevention of disease	XXI - screening, rehab	IT systems, eHealth and mHealth
BT Calendar 1997	Commercial	Synthetic retinal implants for simple vision	8	Rehabilitation	VII - eye	Regenerative medicine
BT Calendar 1997	Commercial	Personal wearable health monitor	6	Health promotion and prevention of disease	XXI - screening, rehab	IT systems, eHealth and mHealth
BT Calendar 1997	Commercial	Artificial heart	13	Treatment and management of symptoms and disease	IX - circulation	Regenerative medicine

BT Calendar 1997	Commercial	Genetic screening widely used	10	Health promotion and prevention of disease	XXI - screening, rehab	Population programmes
BT Calendar 1997	Commercial	Fine particle beam gene engineering	12	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
BT Calendar 1997	Commercial	Artificial senses, sensors directly stimulating nerves	15	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
BT Calendar 1997	Commercial	Prevention of cancer	16	Health promotion and prevention of disease	II - cancers	Population programmes
BT Calendar 1997	Commercial	Custom foods for particular medical conditions will exist.	13	Treatment and management of symptoms and disease	Other - generic	Other
BT Calendar 1997	Commercial	Genetic programs to enhance human well-being	23	Health promotion and prevention of disease	V - mental health	Population programmes
BT Calendar 1997	Commercial	Artificial lungs	18	Treatment and management of symptoms and disease	X - respiratory	Regenerative medicine
BT Calendar 1997	Commercial	Artificial kidneys	18	Treatment and management of symptoms and disease	XIV - genitourina ry	Regenerative medicine
BT Calendar 1997	Commercial	Artificial brain cells	20	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
BT Calendar 1997	Commercial	Artificial liver	23	Treatment and management of symptoms and disease	XI - GI tract, dental health	Regenerative medicine
BT Calendar 1997	Commercial	Extension of average lifespan to over 100	23	Health promotion and prevention of disease	XXI - screening, rehab	Unknown
BT Calendar 1997	Commercial	Artificial brain implants	28	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
BT Calendar 1997	Commercial	Artificial peripheral nerves	28	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
BT Calendar 1997	Commercial	Artificial legs	33	Rehabilitation	XXI - screening, rehab	Unknown

BT Calendar 1997	Commercial	Fully functional artificial eyes	33	Treatment and management of symptoms and disease	VII - eye	Regenerative medicine
BT Calendar 2005	Commercial	laser activated drug capsules	3	Treatment and management of symptoms and disease	Other - generic	drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	ultrasound or radio activated capsules	3	Treatment and management of symptoms and disease	Other - generic	drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	blood analysis chips	3	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
BT Calendar 2005	Commercial	e-Baybies electronic conception	5	Health promotion and prevention of disease	XXI - screening, rehab	Unknown
BT Calendar 2005	Commercial	Instant electronic identification of pathogens	5	Diagnosis and monitoring of disease	I - infections	Diagnostic tests and imaging
BT Calendar 2005	Commercial	Online surgeries dominate first line medical care	5	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	active skin	5	Unknown	XII - skin	Unknown
BT Calendar 2005	Commercial	Cyber-drugs (electronically activated drugs)	5	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	automated pain relief for soldiers	5	Treatment and management of symptoms and disease	XIX - injury	Devices and biomaterials
BT Calendar 2005	Commercial	bacteria in toothpaste to attack plaque	5	Health promotion and prevention of disease	XI - GI tract, dental health	Non-surgical therapy
BT Calendar 2005	Commercial	e-baybies, binary conception	5	Health promotion and prevention of disease	XXI - screening, rehab	Unknown
BT Calendar 2005	Commercial	hand-held scanner to detect tumours using tissue resonance interferometer	5	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
BT Calendar 2005	Commercial	smart pill bottles remotely monitor medication taking and use alarms	5	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth

BT Calendar 2005	Commercial	diabetes cure via stem cell research	5	Treatment and management of symptoms and disease	IV - endocrine	Regenerative medicine
BT Calendar 2005	Commercial	Use of human's own tissues to grow replacement organs	8	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
BT Calendar 2005	Commercial	Artificial senses	8	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
BT Calendar 2005	Commercial	context sensitive cyber drugs	8	Treatment and management of symptoms and disease	Other - generic	Unknown
BT Calendar 2005	Commercial	electronic stimulation of brain sensations as recreational substitute for drugs	8	Other	VI - nervous	Devices and biomaterials
BT Calendar 2005	Commercial	Custom (GM) foods for particular medical conditions will exist.	8	Treatment and management of symptoms and disease	Other - generic	Other
BT Calendar 2005	Commercial	Gene-gel stimulation of re- growth of natural teeth on demand	8	Treatment and management of symptoms and disease	XI - GI tract, dental health	drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	retina regeneration using foetal retinal cell injection	8	Treatment and management of symptoms and disease	VII - eye	Regenerative medicine
BT Calendar 2005	Commercial	tooth regeneration	8	Treatment and management of symptoms and disease	XI - GI tract, dental health	Regenerative medicine
BT Calendar 2005	Commercial	plastic bones	8	Treatment and management of symptoms and disease	XIII - musculoske letal	Devices and biomaterials
BT Calendar 2005	Commercial	emotionally specific drugs	8	Unknown	V - mental health	drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	synthetic organs by printing layers of cells	10	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
BT Calendar 2005	Commercial	synthetic viruses	10	Unknown	1-	Other

					infections	
BT Calendar 2005	Commercial	sensory augmentation using sensory implants, nanoparticles etc	10	Rehabilitation	VI - nervous	Devices and biomaterials
BT Calendar 2005	Commercial	use of stem cells in brain after strokes or accidents	10	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
BT Calendar 2005	Commercial	gene therapy generates new hair cells in humans	10	Treatment and management of symptoms and disease	XII - skin	drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	artificial sensors used in cosmetic upgrade surgery	13	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
BT Calendar 2005	Commercial	Electronic memory enhancement	20	Unknown	Other - generic	Unknown
BT Calendar 2005	Commercial	Nanobots in toothpaste attack plaque	20	Health promotion and prevention of disease	XI - GI tract, dental health	drugs (not prophylactic vaccines)
BT Calendar 2005	Commercial	Fully functioning artificial eyes	20	Treatment and management of symptoms and disease	VII - eye	Regenerative medicine
BT Calendar 2005	Commercial	electronic brain implants	20	Treatment and management of symptoms and disease	VI - nervous	Devices and biomaterials
BT Calendar 2005	Commercial	Intelligence or memory enhancement by external means	20	Unknown	Other - generic	Unknown
BT Calendar 2005	Commercial	e-baybies, genetic conception	20	Health promotion and prevention of disease	XXI - screening, rehab	Unknown
BT Calendar 2005	Commercial	synthetic immune system	20	Treatment and management of symptoms and disease	III - blood	Regenerative medicine
BT Calendar 2005	Commercial	Artificial peripheral nerves	30	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
BT Calendar 2005	Commercial	e-baybies, digital emulation conception	30	Health promotion and prevention of disease	XXI - screening, rehab	Unknown

BT Calendar 2005	Commercial	Electronic prescriptions reduce fraud and improve speed	3	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	24/7 blood chemistry monitoring	3	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
BT Calendar 2005	Commercial	supermarkets used as major source of medical alerts	3	Health promotion and prevention of disease	Other - generic	Other
BT Calendar 2005	Commercial	Expert systems used extensively in GP surgeries	5	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Hospitals use virtual queuing systems	5	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Neural networks used for patient appointment management	5	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Multimedia patient records	5	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Lifestyle monitoring and insurance linked to medical records	5	Health promotion and prevention of disease	Other - generic	Population programmes
BT Calendar 2005	Commercial	antibacterial coatings on domestic appliances, phones etc, especially in hospitals	5	Health promotion and prevention of disease	I - infections	Devices and biomaterials
BT Calendar 2005	Commercial	flexible displays used for body monitoring and alerts	5	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	emotion alerts	5	Health promotion and prevention of disease	Other - generic	Devices and biomaterials
BT Calendar 2005	Commercial	(drug shortages caused by) internet diagnosis	5	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth

BT Calendar 2005	Commercial	MRSA detection	5	Diagnosis and	1-	Population
		chips on sale in high street		monitoring of disease	infections	programmes
BT Calendar 2005	Commercial	Devices roaming within blood vessels under own power	8	Unknown	Other - generic	Devices and biomaterials
BT Calendar 2005	Commercial	Operations videoed and stored as part of medical record	8	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Direct electronic pleasure production	8	Other	V - mental health	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Orgasm by email	8	Supporting patients receiving care (designed to be used by individuals)	XIV - genitourina ry	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Artificial senses, sensors directly stimulating nerves	8	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
BT Calendar 2005	Commercial	Smart membranes for remote control of drug injection	8	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
BT Calendar 2005	Commercial	Domestic bacterial detection devices	8	Health promotion and prevention of disease	I - infections	Diagnostic tests and imaging
BT Calendar 2005	Commercial	Micro-fluidic chips used for gene sequencing in every GP surgery	8	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
BT Calendar 2005	Commercial	Self certification for prescriptions using electronic diagnostics	8	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Visitor sanitising in hospitals	8	Health promotion and prevention of disease	I - infections	Organisational programmes
BT Calendar 2005	Commercial	Outpatients at home - remote tele-medical consultations	8	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
BT Calendar 2005	Commercial	Individual's genome part of their medical record	8	Supporting patients receiving care (designed to be used by	Other - generic	Organisational programmes

				individuals)		
BT Calendar 2005	Commercial	Portable bactericidal devices	10	Health promotion and prevention of disease	I - infections	Medical equipment
BT Calendar 2005	Commercial	Bactericidal saws incorporated onto materials in hospitals	10	Health promotion and prevention of disease	I - infections	Devices and biomaterials
BT Calendar 2005	Commercial	Robotic cleaners in hospitals	10	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Daar et al 2002	Research	Modified molecular technologies for affordable, simple diagnosis of infectious diseases	8	Diagnosis and monitoring of disease	I - infections	Diagnostic tests and imaging
Daar et al 2002	Research	Recombinant technologies to develop vaccines against infectious diseases	8	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Daar et al 2002	Research	Technologies for more efficient drug and vaccine delivery systems	8	Treatment and management of symptoms and disease	Other - generic	Unknown
Daar et al 2002	Research	Technologies for environmental improvement (sanitation, clean water, bioremediation)	8	Health promotion and prevention of disease	Other - generic	Unknown
Daar et al 2002	Research	Female-controlled protection against sexually transmitted diseases, both with and without contraceptive effect	8	Health promotion and prevention of disease	XIV - genitourina ry	Devices and biomaterials
Daar et al 2002	Research	Genetically modified crops with increased nutrients to counter specific deficiencies	8	Health promotion and prevention of disease	IV - endocrine	Unknown

Daar et al 2002	Research	Recombinant technology to make therapeutic products (for example, insulin, interferons) more affordable	8	Treatment and management of symptoms and disease	Other - generic	drugs (not prophylactic vaccines)
Karim2000	Policy planning	Telemedicine	15	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Karim2000	Policy planning	Medical databases	15	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Karim2000	Policy planning	Expert System in managed care and preventive medicine	15	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Karim2000	Policy planning	diagnostic procedures (e.g. recombinant DNA techniques for parental screening)	15	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Karim2000	Policy planning	Therapeutic procedures (e.g. microsurgery and implanted muscle stimulators).	15	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Karim2000	Policy planning	Nanotechnology (e.g. devices which interact with tissues within the body to boost the immune system).	15	Treatment and management of symptoms and disease	III - blood	Devices and biomaterials
Karim2000	Policy planning	Vaccines against infectious diseases	15	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Karim2000	Policy planning	Development of an AIDS vaccine	15	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Karim2000	Policy planning	Development of a TB vaccine	15	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Karim2000	Policy planning	Health promotion targeted at the youth	15	Health promotion and prevention of disease	Other - generic	Population programmes

Karim2000	Policy planning	Development of enriched and fortified staple foods	15	Health promotion and prevention of disease	Other - generic	Population programmes
Karim2000	Policy planning	Development of a malaria vaccine	15	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Karim2000	Policy planning	Development of on-site diagnostic tools	15	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Karim2000	Policy planning	Development of female contraceptives	15	Health promotion and prevention of disease	XXI - screening, rehab	drugs (not prophylactic vaccines)
Karim2000	Policy planning	Development of barrier methods and microbicides for sexually transmitted diseases and HIV	15	Health promotion and prevention of disease	I - infections	Devices and biomaterials
Karim2000	Policy planning	Development of malaria drugs	15	Treatment and management of symptoms and disease	I - infections	drugs (not prophylactic vaccines)
Karim2000	Policy planning	Development of new TB drugs	15	Treatment and management of symptoms and disease	I - infections	drugs (not prophylactic vaccines)
Karim2000	Policy planning	Self management tools for chronic diseases (e.g. hypertension, diabetes, diarrhoea, psychiatric conditions)	15	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Organisational programmes
Karim2000	Policy planning	Tissue regeneration and gene therapy	15	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Sbipy 1988	Research	Monoclonal antibodies will be used in: Histopathological techniques	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Monoclonal antibodies will be used in: Biochemical techniques	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Monoclonal antibodies will be	0	Diagnosis and monitoring of	Other - generic	Diagnostic tests and imaging

		used in: in-vivo diagnostic techniques		disease		
Sbipy 1988	Research	Monoclonal antibodies will be used in: Identification and localization of tumours	0	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
Sbipy 1988	Research	Gene probes will be used in: diagnostic microbiology	0	Diagnosis and monitoring of disease	I - infections	Diagnostic tests and imaging
Sbipy 1988	Research	Gene probes will be used in: diagnostic virology	0	Diagnosis and monitoring of disease	I - infections	Diagnostic tests and imaging
Sbipy 1988	Research	Gene probes will be used in: To screen for potentially deleterious genes*	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Gene probes will be used in: Diagnosing most genetic disorders	10	Diagnosis and monitoring of disease	XVII - congenital	Diagnostic tests and imaging
Sbipy 1988	Research	Genetic engineering will enable the isolation of high risk groups for common diseases	10	Health promotion and prevention of disease	Other - generic	Population programmes
Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: Ultrasound	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: Doppler measurement	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: CT scanning	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging

Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: NMR scanning	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: Nuclear medicine	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: Positron detection*	0	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Imaging techniques will be in widespread and less hazardous use including: Three- dimensional dynamic imaging	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Sbipy 1988	Research	Drug therapy will be enhanced by: Genetic engineering	10	Treatment and management of symptoms and disease	Other - generic	drugs (not prophylactic vaccines)
Sbipy 1988	Research	Drug therapy will be enhanced by: Monoclonal antibodies used for drug targeting	10	Treatment and management of symptoms and disease	Other - generic	drugs (not prophylactic vaccines)
Sbipy 1988	Research	Drug delivery devices with or without in-vivo sensors	10	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
Sbipy 1988	Research	More effective Therapeutics will be available for: Viral infections	0	Treatment and management of symptoms and disease	I - infections	drugs (not prophylactic vaccines)
Sbipy 1988	Research	More effective Therapeutics will be available for: Autoimmune diseases (monoclonal antibodies)	10	Treatment and management of symptoms and disease	III - blood	drugs (not prophylactic vaccines)
Sbipy 1988	Research	More effective Therapeutics will	0	Treatment and management of	IX - circulation	drugs (not prophylactic

		be available for: Heart failure		symptoms and disease		vaccines)
		(better drugs)				
Sbipy 1988	Research	More effective	10	Treatment and	IX -	drugs (not
		Therapeutics will		management of	circulation	prophylactic
		be available for:		symptoms and		vaccines)
		Obstructive		disease		,
		arterial lesions (by				
		removal and				
		control of				
		platelets and				
		synthetic vascular				
		prostheses)				
Sbipy 1988	Research	Cancer	10	Other	II - cancers	Other
5.6.107		(hyperthermia,				
		growth regulation				
		factors and				
		monoclonal				
		antibodies)				
Sbipy 1988	Research	Cardiac	10	Treatment and	IX -	Devices and
		arrhythmias		management of	circulation	biomaterials
		(implantable		symptoms and		
		mechanisms)		disease		
Sbipy 1988	Research	More effective	0	Treatment and	XIII -	Devices and
		Therapeutics will		management of	musculoske	biomaterials
		be available for:		symptoms and	letal	
		Arthritic joints		disease		
		(more				
		biocompatible				
		prosthetic				
		materials and a				
		wider range of				
		joint				
		replacements)				
Sbipy 1988	Research	More effective	0	treatment and	XIV -	Devices and
		Therapeutics will		management of	genitourina	biomaterials
		be available for:		symptoms and	ry	
		Incontinence		disease		
		(stimulation via				
		implantable				
		electrodes)				
Sbipy 1988	Research	More effective	0	Rehabilitation	Other -	Other
		Therapeutics will			generic	
		be available for:				
		Disability (wider				
		range of flow				
		technology aids				
		and biological				
		servomechanisms				
		linked to				
		computers and				

		robotics)				
Sbipy 1988	Research	More effective Therapeutics will be available for: Limb damage (permanent internal bone repair)	0	Treatment and management of symptoms and disease	XIII - musculoske letal	Devices and biomaterials
Sbipy 1988	Research	More effective Therapeutics will be available for: Tropical parasitic diseases (vaccines)	0	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Sbipy 1988	Research	More effective Therapeutics will be available for: Mental disorders (neurotransmitter s)	10	Treatment and management of symptoms and disease	V - mental health	drugs (not prophylactic vaccines)
Sbipy 1988	Research	Laser microsurgery	0	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Sbipy 1988	Research	Laser endoscopic surgery	0	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Sbipy 1988	Research	Laser angioplasty and angiography	0	Treatment and management of symptoms and disease	IX - circulation	Therapeutic procedures
Sbipy 1988	Research	Other laser and endoscopic surgical techniques	10	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Sbipy 1988	Research	Cryosurgery	10	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Sbipy 1988	Research	Lithotripsy	10	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Sbipy 1988	Research	Transplantation will be enhanced by better techniques	0	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials

			1		l .	1
		enabling long				
		term in-vitro				
		organ				
		preservation and				
		the prevention of				
		rejection				
Sbipy 1988	Research	Bone marrow	0	Treatment and	III - blood	Regenerative
		transplantation		management of		medicine
		with purified stem		symptoms and		
		cells and		disease		
		autologous				
		material will be				
		available				
Sbipy 1988	Research	A safe male pill for	10	Health promotion	XXI -	drugs (not
361py 1366	Research	long-term use will	10	and prevention of	screening,	prophylactic
		be available		disease	rehab	
Chim. 1000	Dogganah		0		XIV -	vaccines)
Sbipy 1988	Research	Improved	U	Diagnosis and		Diagnostic tests
		techniques for		monitoring of	genitourina	and imaging
		detecting		disease	ry	
		ovulation will				
		enhance natural				
_	_	family planning*		_		
Sbipy 1988	Research	Optical disc	0	Supporting the	Other -	Diagnostic tests
		storage and		provision of care	generic	and imaging
		communication		and/or increasing		
		will be used with		service efficiency		
		X-rays and other				
		diagnostic images				
Sbipy 1988	Research	Computers will be	10	Supporting the	Other -	IT systems, eHealth
		used by clinical		provision of care	generic	and mHealth
		departments for		and/or increasing		
		data collection		service efficiency		
Sbipy 1988	Research	Expert	0	Supporting the	Other -	IT systems, eHealth
		interrogation will		provision of care	generic	and mHealth
		be possible due to		and/or increasing		
		data		service efficiency		
		centralization		,		
Sbipy 1988	Research	Patient	10	Supporting	Other -	IT systems, eHealth
, , , , , , , , , , , , , , , , , , , ,		interviewing		patients receiving	generic	and mHealth
		systems will be		care (designed to	0	
		available in the		be used by		
		surgery and in		individuals)		
		patients' homes				
Sbipy 1988	Research	Expert systems	10	Supporting	Other -	IT systems, eHealth
351PY 1300	Research	will enable	10	patients receiving	generic	and mHealth
		diagnosis and		care (designed to	Benefic	and minealth
		define the most		be used by		
				•		
		applicable		individuals)		
		treatment				1

Sbipy 1988	Research	Linkage of computerized patient data will be available between all hospital, community and primary care services and settings	10	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Life style changing behaviours	N/A	Health promotion and prevention of disease	Other - generic	Population programmes
STG 1988	Policy planning	Screening for phenylketonuria	N/A	Health promotion and prevention of disease	IV - endocrine	Population programmes
STG 1988	Policy planning	Screening for congenital hypothyroidism	N/A	Health promotion and prevention of disease	IV - endocrine	Population programmes
STG 1988	Policy planning	Blood pressure can be checked by self-service meters	N/A	Diagnosis and monitoring of disease	IX - circulation	Diagnostic tests and imaging
STG 1988	Policy planning	High serum cholesterol can be checked by fingerprick blood test	N/A	Diagnosis and monitoring of disease	IX - circulation	Diagnostic tests and imaging
STG 1988	Policy planning	Certain cancer tests can be self- administered	N/A	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
STG 1988	Policy planning	Improved diagnostic tests may be available for widespread use for screening at the community level	N/A	Health promotion and prevention of disease	Other - generic	Population programmes
STG 1988	Policy planning	Improved vaccine against cholera in the tropical developing countries	N/A	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
STG 1988	Policy planning	New malaria vaccine in the tropical developing countries	N/A	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
STG 1988	Policy planning	New vaccine against hepatitus B	N/A	Health promotion and prevention of disease	I - infections	Prophylactic vaccines

STG 1988	Policy	New vaccine	N/A	Health promotion	1 -	Prophylactic
	planning	against		and prevention of	infections	vaccines
		respiratory		disease		
		syncytial virus				
STG 1988	Policy	New vaccine	N/A	Health promotion	1-	Prophylactic
	planning	against influenza		and prevention of	infections	vaccines
				disease		
STG 1988	Policy	New vaccine	N/A	Health promotion	1-	Prophylactic
	planning	against AIDS		and prevention of	infections	vaccines
CTC 4000	Dalia.	Niamonatina	N1 / A	disease		Dua ale da etia
STG 1988	Policy	New vaccine	N/A	Health promotion	I - infections	Prophylactic vaccines
	planning	against cytomegalovirus		and prevention of disease	infections	vaccines
STG 1988	Policy	Better vaccine	N/A	Health promotion	1-	Prophylactic
310 1988	planning	against Perussis	IN/A	and prevention of	infections	vaccines
	planning	against i ci assis		disease	IIIICCLIOIIS	Vaccines
STG 1988	Policy	Oral	N/A	Health promotion	1-	Prophylactic
3.01300	planning	administration or	'','	and prevention of	infections	vaccines
		administartion by		disease		
		nasal spray will				
		facilitate mass				
		immunization				
STG 1988	Policy	Creating vaccines	N/A	Health promotion	1 -	Prophylactic
	planning	containing		and prevention of	infections	vaccines
		antigens for		disease		
		several organisms				
		given together				
STC 4000	Dalia.	(e.g. DPTPM)	N1 / A	I I a a la la como con a abi a co	Oth su	Danielatian
STG 1988	Policy	Shifts in diet toward lower	N/A	Health promotion and prevention of	Other -	Population
	planning	intake of fat		disease	generic	programmes
		especially		uisease		
		saturated fat				
STG 1988	Policy	Reliable and	N/A	Diagnosis and	IX -	Diagnostic tests
0.0 2000	planning	simple test for	,	monitoring of	circulation	and imaging
		cholesterol		disease		
STG 1988	Policy	More effective	N/A	Health promotion	IX -	drugs (not
	planning	and safer drugs		and prevention of	circulation	prophylactic
		for treatment of		disease		vaccines)
		elevated				
		cholesterol				
STG 1988	Policy	Technologies for	N/A	Supporting	Other -	Diagnostic tests
	planning	home use without		patients receiving	generic	and imaging
		professional		care (designed to		
		supervision (e.g.		be used by		
		home diagnostic		individuals)		
STG 1988	Policy	kits) Disease conditions	N/A	Supporting	Other -	IT systems, allealth
310 1300	Policy	will be monitored	IN/A	Supporting patients receiving		IT systems, eHealth and mHealth
	planning	from distant		care (designed to	generic	and minealul
		professional sites		be used by		
		professional sites	1	De asea by		

				individuals)		
STG 1988	Policy planning	Robotics will be used for mobility and assistance at home such as nutrition and cleaning	N/A	Rehabilitation	Other - generic	Assistive devices
STG 1988	Policy planning	Regeneration of central nervous system through the use of nerve growth factors or transplant neurotransmitter-producing cells into the brain	N/A	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
STG 1988	Policy planning	Grafting of the spinal cord or the peripheral nervous system	N/A	Treatment and management of symptoms and disease	VI - nervous	Therapeutic procedures
STG 1988	Policy planning	More safer & effective contraception	N/A	Health promotion and prevention of disease	XXI - screening, rehab	Drugs (not prophylactic vaccines)
STG 1988	Policy planning	Contraceptive vaccine	N/A	Health promotion and prevention of disease	XXI - screening, rehab	Prophylactic vaccines
STG 1988	Policy planning	Alternatives to surgical abortion such as combination of antiprogestins and prostaglandins	N/A	Treatment and management of symptoms and disease	XV - pregnancy	drugs (not prophylactic vaccines)
STG 1988	Policy planning	Treatment of infertility using new technologies such as in vitro fertilization, surrogate motherhood, freezing of germ cells and embro with embryo transfer	N/A	Treatment and management of symptoms and disease	XIV - genitourina ry	Other
STG 1988	Policy planning	Fetal cells can be isolated from the mother's bloodstream as a method for prenatal screening	N/A	Health promotion and prevention of disease	XXI - screening, rehab	Diagnostic tests and imaging

STG 1988	Policy planning	Metabolic, physiologic information can	N/A	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
STG 1988	Policy	be obtained by spectroscopy  Data from CT	N/A	Supporting	Other -	Diagnostic tests
	planning	scanner will be stored on a disk, transmit by a phone line or othe communication		patients receiving care (designed to be used by individuals)	generic	and imaging
STG 1988	Policy planning	Film may disappear and computer will directly interpret the diagnosis	N/A	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Diagnostic tests and imaging
STG 1988	Policy planning	Biosensors to monitor disease condition or results of therapy (e.g. diabetes)	N/A	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
STG 1988	Policy planning	Tumor markers that can be measured in blood	N/A	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
STG 1988	Policy planning	Flow cytometer will be used in transplantation or monitoring of cancer therapy	N/A	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
STG 1988	Policy planning	Monoclonal antibodies for diagnosis such as colon cancer and area of cardiac infarctions	N/A	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
STG 1988	Policy planning	Human gene therapy for a wide variety of diseases including cancer, diabetes, cardiovascular and affective disorders such as depression	N/A	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
STG 1988	Policy planning	DNA probe for intra-uterine diagnosis of genetic diseases	N/A	Diagnosis and monitoring of disease	XVII - congenital	Diagnostic tests and imaging
STG 1988	Policy planning	Home diagnostic kits for sexually	7	Diagnosis and monitoring of	I - infections	Organisational programmes

		transmitted diseases and hepatitits		disease		
STG 1988	Policy planning	Home diagnostic kits for screening for cancer	7	Diagnosis and monitoring of disease	I - infections	Organisational programmes
STG 1988	Policy planning	Home diagnostic kits to test for common diseases with genetic basis such as diabetes	N/A	Diagnosis and monitoring of disease	Other - generic	Organisational programmes
STG 1988	Policy planning	Genetic insertion therapy for treatment of certain blood disorders such as thalassaemia and sickle cell anaemia	N/A	Treatment and management of symptoms and disease	III - blood	Regenerative medicine
STG 1988	Policy planning	Oral treatment forms for hormones, enzymes and other peptides may be developed	N/A	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
STG 1988	Policy planning	New drugs for asthma	N/A	Treatment and management of symptoms and disease	X - respiratory	Drugs (not prophylactic vaccines)
STG 1988	Policy planning	New drugs for coronary artery diseases	N/A	Treatment and management of symptoms and disease	IX - circulation	Drugs (not prophylactic vaccines)
STG 1988	Policy planning	Monoclonal antibodies to replace immune globulins	N/A	Treatment and management of symptoms and disease	III - blood	Drugs (not prophylactic vaccines)
STG 1988	Policy planning	Cloning of skin	N/A	Treatment and management of symptoms and disease	XII - skin	Regenerative medicine
STG 1988	Policy planning	Growth of retinal tissue and corneal endothelium	N/A	Treatment and management of symptoms and disease	VII - eye	Regenerative medicine
STG 1988	Policy planning	Total body irradiation for transplant (to prevent rejection)	N/A	Treatment and management of symptoms and disease	III - blood	Non-surgical therapy
STG 1988	Policy planning	Artificial heart	N/A	Treatment and management of symptoms and	IX - circulation	Regenerative medicine

				disease		
STG 1988	Policy planning	Artificial pancreas	N/A	Treatment and management of symptoms and disease	IV - endocrine	Regenerative medicine
STG 1988	Policy planning	Shoulder joint replacement	N/A	Treatment and management of symptoms and disease	XIII - musculoske letal	Devices and biomaterials
STG 1988	Policy planning	Cochlear implants	N/A	Treatment and management of symptoms and disease	VIII - ear	Devices and biomaterials
STG 1988	Policy planning	Coating of implant materials to improve acceptability	N/A	Other	Other - generic	Devices and biomaterials
STG 1988	Policy planning	Functional electrical stimulation in prosthetics allowing brain to control the action	N/A	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
STG 1988	Policy planning	Prostheic fingers	N/A	Rehabilitation	XIII - musculoske letal	Devices and biomaterials
STG 1988	Policy planning	Organ transplant and improvement of functional activities of organs (pancreas, bone, small bowel, endocine glands)	N/A	Treatment and management of symptoms and disease	Other - generic	Other
STG 1988	Policy planning	Microprocessor to restore damaged areas of the brain	N/A	Rehabilitation	VI - nervous	Devices and biomaterials
STG 1988	Policy planning	Laser cytofluorometry will be used to identify RNA and DNA in the plasma	N/A	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
STG 1988	Policy planning	Laser doppler to measure blood flow in the retina	N/A	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
STG 1988	Policy planning	Laser to stop gastrointestinal bleeding	N/A	Treatment and management of symptoms and disease	XI - GI tract, dental health	Therapeutic procedures

STG 1988	Policy planning	Laser to break urinary stones	N/A	Treatment and management of	XIV - genitourina	Therapeutic procedures
	piaiiiiig	urmary stories		symptoms and disease	ry	procedures
STG 1988	Policy planning	Laser surgery through endoscope	N/A	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
STG 1988	Policy planning	Widespread use of microsurgery	N/A	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
STG 1988	Policy planning	Electronic gas valve regulator for safety in anaesthaesia	N/A	Supporting the provision of care and/or increasing service efficiency	XIX - injury	Medical equipment
STG 1988	Policy planning	Instantaneous measurement of blood gases and drug levels in the body during anasthaesia	N/A	Supporting patients receiving care (designed to be used by individuals)	XIX - injury	Diagnostic tests and imaging
STG 1988	Policy planning	Computerised ECG operating room	N/A	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Data on each patient available at any moment during the operation	N/A	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Computerised electroanaesthesi a	N/A	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	New methods to close wounds e.g. tissue glue with ultrasound	N/A	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
STG 1988	Policy planning	Spectroscopy using optical methods to diagnose caries	N/A	Diagnosis and monitoring of disease	XI - GI tract, dental health	Diagnostic tests and imaging
STG 1988	Policy planning	Bone like implants for teeth and bones	N/A	Treatment and management of symptoms and disease	XI - GI tract, dental health	Devices and biomaterials
STG 1988	Policy planning	Home monitoring especially of the elderly	N/A	Supporting patients receiving care (designed to	Other - generic	IT systems, eHealth and mHealth

				be used by individuals)		
				·		
STG 1988	Policy planning	Networks for communications between and within hospitals	N/A	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Huge mass memories (e.g. on laser disc) for the storage of medical records	N/A	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Video disk oriented data base for medical records	N/A	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Computer aided examination and testing	N/A	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
STG 1988	Policy planning	Improved biomaterials for joint implants and plastic surgery	N/A	Treatment and management of symptoms and disease	XIII - musculoske letal	Devices and biomaterials
STG 1988	Policy planning	Improved materials for artificial blood vessels	N/A	Treatment and management of symptoms and disease	IX - circulation	Devices and biomaterials
Cahill et al Technology Map 1999	policy planning	Therapeutics for arterial occlusion and myocardial infarction	4	Treatment and management of symptoms and disease	IX - circulation	Drugs (not prophylactic vaccines)
Cahill et al Technology Map 1999	Policy planning	Guidelines for adult disease preventing life style	8	Supporting the provision of care and/or increasing service efficiency	XXI - screening, rehab	Organisational programmes
Cahill et al Technology Map 1999	policy planning	Development of anti-cancer agents (gene level)	11	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Cahill et al Technology Map 1999	policy planning	drugs preventing the occurrence of cancer	12	Health promotion and prevention of disease	II - cancers	Drugs (not prophylactic vaccines)
Cahill et al Technology Map 1999	policy planning	Effective means to prevent metastasis	15	Health promotion and prevention of disease	II - cancers	Unknown
Cahill et al Technology Map 1999	policy planning	Genetic/biochemi cal tests for schizophrenia and depression	9	Diagnosis and monitoring of disease	VI - nervous	Diagnostic tests and imaging

Food and Drug	Policy	Biosensors	10	Unknown	Other -	Diagnostic tests
Administration	planning				generic	and imaging
(FDA) surveys						
1998						
Food and Drug	Policy	Laser diagnosis	10	Diagnosis and	Other -	Diagnostic tests
Administration	planning			monitoring of	generic	and imaging
(FDA) surveys				disease		
1998						
Food and Drug	Policy	Tissue engineered	10	Treatment and	Other -	Devices and
Administration	planning	devices		management of	generic	biomaterials
(FDA) surveys				symptoms and		
1998		DI I	40	disease	DV.	
Food and Drug	Policy	Blood vessel	10	Treatment and	IX -	Regenerative
Administration	planning	prosthetics		management of	circulation	medicine
(FDA) surveys				symptoms and		
1998	Dalia	Dana anasthatias/	10	disease	VIII	Danas anatica
Food and Drug	Policy	Bone prosthetics/	10	Treatment and	XIII -	Regenerative
Administration	planning	growth		management of	musculoske	medicine
(FDA) surveys				symptoms and disease	letal	
1998	Doline	Cardiac	10	Treatment and	IX -	Unknown
Food and Drug  Administration	Policy		10			Unknown
	planning	stimulation		management of	circulation	
(FDA) surveys 1998				symptoms and disease		
Food and Drug	Policy	cartilage	10	Treatment and	XIII -	Devices and
Administration	planning	prosthetics	10	management of	musculoske	biomaterials
	piailillig	prostrictics		symptoms and	letal	Diomaterials
(FDA) surveys 1998				disease	letai	
Food and Drug	Policy	Computer aided	10	Diagnosis and	Other -	IT systems, eHealth
Administration	planning	clinical labs	10	monitoring of	generic	and mHealth
(FDA) surveys	Pidiming	cirrical labs		disease	generic	
1998				discuse		
Food and Drug	Policy	Computer aided	10	Supporting the	Other -	IT systems, eHealth
Administration	planning	diagnosis	10	provision of care	generic	and mHealth
(FDA) surveys	, p.c	u.ugosis		and/or increasing	80	
1998				service efficiency		
Food and Drug	Policy	Telemedicine	10	Supporting	Other -	IT systems, eHealth
Administration	planning			patients receiving	generic	and mHealth
(FDA) surveys				care (designed to		
1998				be used by		
				individuals)		
Food and Drug	Policy	Drug impregnated	10	Treatment and	Other -	Devices and
Administration	planning	devices		management of	generic	biomaterials
(FDA) surveys				symptoms and		
1998				disease		
Food and Drug	Policy	Endoscopy	10	Diagnosis and	Other -	Diagnostic tests
Administration	planning			monitoring of	generic	and imaging
(FDA) surveys				disease		
1998						
Food and Drug	Policy	Hearing	10	Rehabilitation	VIII - ear	Devices and
Administration	planning	aids/Nonimplante				biomaterials

(FDA) surveys 1998		d sensory aids				
Food and Drug Administration (FDA) surveys 1998	Policy planning	Heart valves	10	Treatment and management of symptoms and disease	IX - circulation	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Heart pumps	10	Treatment and management of symptoms and disease	IX - circulation	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Home diagnostics /Home/self monitoring & diagnosis	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Organisational programmes
Food and Drug Administration (FDA) surveys 1998	Policy planning	Image contrast agents	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Integrated patient medical info systems	10	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Laser treatment	10	Treatment and management of symptoms and disease	Other - generic	Non-surgical therapy
Food and Drug Administration (FDA) surveys 1998	Policy planning	kidney prosthetics	10	Treatment and management of symptoms and disease	XIV - genitourina ry	Regenerative medicine
Food and Drug Administration (FDA) surveys 1998	Policy planning	Laser surgery	10	Treatment and management of symptoms and disease	Other - generic	Non-surgical therapy
Food and Drug Administration (FDA) surveys 1998	Policy planning	Liver prosthetics	10	Treatment and management of symptoms and disease	XI - GI tract, dental health	Regenerative medicine
Food and Drug Administration (FDA) surveys 1998	Policy planning	Mini invasive neurosurgery	10	Treatment and management of symptoms and disease	VI - nervous	Therapeutic procedures
Food and Drug Administration (FDA) surveys 1998	Policy planning	Mini invasive cardiac surgery	10	Treatment and management of symptoms and disease	IX - circulation	Therapeutic procedures
Food and Drug Administration (FDA) surveys 1998	Policy planning	MRI	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging

Food and Drug Administration (FDA) surveys 1998	Policy planning	Neuromuscular stimulation	10	Treatment and management of symptoms and disease	Other - generic	Non-surgical therapy
Food and Drug Administration (FDA) surveys 1998	Policy planning	Nerve regeneration	10	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
Food and Drug Administration (FDA) surveys 1998	Policy planning	Neural stimulation	10	Treatment and management of symptoms and disease	VI - nervous	Non-surgical therapy
Food and Drug Administration (FDA) surveys 1998	Policy planning	Ocular prosthetics	10	Treatment and management of symptoms and disease	VII - eye	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Pancreas prosthetics	10	Treatment and management of symptoms and disease	IV - endocrine	Regenerative medicine
Food and Drug Administration (FDA) surveys 1998	Policy planning	Patient smart cards	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Robotic surgery	10	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Food and Drug Administration (FDA) surveys 1998	Policy planning	Skin prosthetics	10	Treatment and management of symptoms and disease	XII - skin	Regenerative medicine
Food and Drug Administration (FDA) surveys 1998	Policy planning	Telemedicine- home use	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Telemedicine- radiology	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 2008	Policy planning	Robotic surgical systems	0	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Food and Drug Administration (FDA) surveys 1998	Policy planning	Point-of-care products	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging

Food and Drug Administration (FDA) surveys 1998	Policy planning	Computer- assisted diagnostic systems	10	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Neuro-sensory devices	10	Diagnosis and monitoring of disease	VI - nervous	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Optical diagnostic products	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Integrated electronic patient medical records	10	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Remote patient monitoring systems	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Glucose monitoring products	10	Diagnosis and monitoring of disease	IV - endocrine	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Tissue engineered products	10	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Food and Drug Administration (FDA) surveys 1998	Policy planning	Advanced prosthetic limbs	10	Rehabilitation	XIII - musculoske letal	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Minimally invasive implants (e.g., percutaneous or natural orifice delivery)	10	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Virtual reality systems for immersive training and other applications	10	Unknown	Other - generic	IT systems, eHealth and mHealth
Food and Drug Administration (FDA) surveys 1998	Policy planning	Optical therapeutic devices	10	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Internet-based medical device systems	10	Supporting patients receiving care (designed to be used by	Other - generic	IT systems, eHealth and mHealth

				individuals)		
Food and Drug Administration (FDA) surveys 1998	Policy planning	New (non-eluting) drug delivery systems	10	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Food and Drug Administration (FDA) surveys 1998	Policy planning	Robotic prosthetics	20	Rehabilitation	Other - generic	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	New types of insulin pumps and delivery systems	20	Treatment and management of symptoms and disease	IV - endocrine	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	New types of stents	20	Treatment and management of symptoms and disease	IX - circulation	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Joint replacements	20	Treatment and management of symptoms and disease	XIII - musculoske letal	Devices and biomaterials
Food and Drug Administration (FDA) surveys 1998	Policy planning	Image-guided therapy systems	20	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Food and Drug Administration (FDA) surveys 1998	Policy planning	Advanced ultrasound imaging systems	20	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Advanced optical imaging systems	20	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Advanced MR imaging systems	20	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Minimally invasive radiotherapy systems	20	Treatment and management of symptoms and disease	II - cancers	Non-surgical therapy
Food and Drug Administration (FDA) surveys 1998	Policy planning	Genetic diagnostic products	20	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Food and Drug Administration (FDA) surveys 1998	Policy planning	Remote patient monitoring systems	20	Supporting patients receiving care (designed to be used by	Other - generic	IT systems, eHealth and mHealth

				individuals)		
Institute of the Future, 2009	Research	Bio-marker based tools will screen for future disease risk and produce new diagnoses based on probabilities	11	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Institute of the Future, 2009	Research	Visualizations improve diet & exercise	11	Health promotion and prevention of disease	Other - generic	Non-surgical therapy
Institute of the Future, 2009	Research	GPS-enabled asthma inhalers	11	Supporting the provision of care and/or increasing service efficiency	X - respiratory	IT systems, eHealth and mHealth
Institute of the Future, 2009	Research	Workplace clinics	11	Health promotion and prevention of disease	Other - generic	Organisational programmes
Institute of the Future, 2009	Research	Urban planning for walkability, pollution reduction, neighbourood food systems	11	Health promotion and prevention of disease	Other - generic	Population programmes
Institute of the Future, 2009	Research	Report cards include Body Mass Index (BMI) scores	11	Health promotion and prevention of disease	Other - generic	Population programmes
Institute of the Future, 2009	Research	iPhone-synched medical devices	11	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Institute of the Future, 2009	Research	Quantifying, visualizing, and mapping health implications of environments	11	Health promotion and prevention of disease	Other - generic	Population programmes
Institute of the Future, 2009	Research	Deep brain stimulation used for neurological, behavioral issues	11	Treatment and management of symptoms and disease	VI - nervous	Devices and biomaterials
Institute of the Future, 2009	Research	Home sensors for elder care	11	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Institute of the Future, 2009	Research	Individually targeted therapies	11	Treatment and management of symptoms and	Other - generic	Drugs (not prophylactic vaccines)

				disease		
Institute of the Future, 2009	Research	Sensors track drug efficacy	11	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Devices and biomaterials
Institute of the Future, 2009	Research	Genotypic diagnostics and risk	11	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Institute of the Future, 2009	Research	New technologies enable individuals to experience the future effects of present-day behavior choices	11	Treatment and management of symptoms and disease	Other - generic	Unknown
Institute of the Future, 2009	Research	Regenerative medicine (general)will replace, restore, maintain, or enhance tissue and organ functions	11	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Institute of the Future, 2009	Research	New ways of reliably measuring subjective states such as happiness, anxiety, or pain, and finding the neural correlates of personality and behavioral patterns	11	Diagnosis and monitoring of disease	VI - nervous	Diagnostic tests and imaging
Institute of the Future, 2009	Research	prototype of a prosthetic arm that can be controlled naturally and provide sensory feedback.	11	Rehabilitation	XIII - musculoske letal	Devices and biomaterials
Stevens et al 1997	Research	Magnetic resonance imaging	1	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Stevens et al 1997	Research	Minimally invasive surgery	1	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Stevens et al 1997	Research	drugs for Therapeutic refractory	1	Treatment and management of symptoms and	V - mental health	Drugs (not prophylactic vaccines)

		schizphrenia		disease		
Stevens et al 1997	Research	Implantable vascular stents	1	Treatment and management of symptoms and disease	IX - circulation	Devices and biomaterials
Stevens et al 1997	Research	Peripheral blood stem cells transplantation	1	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Stevens et al 1997	Research	Laser Therapeutic of benign prostatic hyperplasia	1	Treatment and management of symptoms and disease	XIV - genitourina ry	Non-surgical therapy
Stevens et al 1997	Research	Gene therapy advances	4	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Stevens et al 1997	Research	Polymerase chain reaction	4	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Stevens et al 1997	Research	Telemedicine	4	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Stevens et al 1997	Research	Interventional radiology	1	Treatment and management of symptoms and disease	Other - generic	Non-surgical therapy
Stevens et al 1997	Research	Angioplasty	1	Treatment and management of symptoms and disease	IX - circulation	Therapeutic procedures
Stevens et al 1997	Research	Interferon for chronic granulocytic leukemia	1	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	Interferon for hepatitis C	1	Treatment and management of symptoms and disease	I - infections	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	Lasers for dermatology	1	Treatment and management of symptoms and disease	XII - skin	Devices and biomaterials
Stevens et al 1997	Research	Adjuvant chemotherapy in lung cancer	4	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)

	<u> </u>	T	Τ	1	0.1	15
Stevens et al	Research	Near patient	2	Diagnosis and	Other -	Diagnostic tests
1997		testing		monitoring of	generic	and imaging
				disease		
Stevens et al	Research	Revision of joint	1	Treatment and	XIII -	Therapeutic
1997		replacement		management of	musculoske	procedures
		,		symptoms and	letal	
				disease		
Stevens et al	Research	Genetic screening	4	Diagnosis and	Other -	Diagnostic tests
1997	Research	Genetic screening	'	monitoring of	generic	and imaging
1337				disease	generic	and imaging
Stevens et al	Research	Helicobactor	1	Treatment and	1-	Drugs (not
	Research		1			<u> </u>
1997		pylori eradication		management of	infections	prophylactic
				symptoms and		vaccines)
				disease		
Stevens et al	Research	Positron emission	4	Diagnosis and	Other -	Diagnostic tests
1997		tomography		monitoring of	generic	and imaging
				disease		
Stevens et al	Research	Phacoemulsificati	1	Treatment and	VII - eye	Therapeutic
1997		on		management of		procedures
				symptoms and		
				disease		
Stevens et al	Research	Cochlear implants	1	Rehabilitation	VIII - ear	Devices and
1997						biomaterials
Stevens et al	Research	Paclitaxels for	2	Treatment and	II - cancers	Drugs (not
1997	Research	ovarian & breast	_	management of	ii caricers	prophylactic
1337		cancer		symptoms and		vaccines)
		Cancer		disease		vaccines)
Ctovono ot al	Descende	Dana	1		VIII	Diagnostic tosts
Stevens et al	Research	Bone	1	Diagnosis and	XIII -	Diagnostic tests
1997		densitometry		monitoring of	musculoske	and imaging
		screening		disease	letal	
Stevens et al	Research	Anticoagulants for	1	Health promotion	IX -	Drugs (not
1997		atrial fibrillation		and prevention of	circulation	prophylactic
				disease		vaccines)
Stevens et al	Research	Picture archiving	4	Supporting the	Other -	IT systems, eHealth
1997		and		provision of care	generic	and mHealth
		communication		and/or increasing		
		system		service efficiency		
Stevens et al	Research	rhDNase	2	Treatment and	IV -	Drugs (not
1997				management of	endocrine	prophylactic
				symptoms and		vaccines)
				disease		, accines,
Stevens et al	Research	Biomaterials in	2	Treatment and	XIII -	Devices and
1997	Research	bone and joint			musculoske	biomaterials
1331				management of	letal	טוטווומנפוזמוט
		replacement		symptoms and	letai	
Charrent	Davis 1	In an a second of	1	disease	11	Daving / call
Stevens et al	Research	Increased use of	2	Treatment and	II - cancers	Drugs (not
1997		adjuvant		management of		prophylactic
		chemotherapy in		symptoms and		vaccines)
		colorectal cancer		disease		
Stevens et al	Research	Increased use of	2	Treatment and	III - blood	Drugs (not
1997		high purity factor		management of		prophylactic

		VIII and		symptoms and		vaccines)
		recombinant factor VIII in hemophilia		disease		
Stevens et al 1997	Research	Mirena intrauterine contraceptive device	2	Health promotion and prevention of disease	XIV - genitourina ry	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	Adjuvant chemotherapy in lung cancer	4	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	drugs for Alzheimer's disease	6	Treatment and management of symptoms and disease	V - mental health	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	Xenotransplantati on	6	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Stevens et al 1997	Research	Screening for abdominal aortic aneurysm	6	Health promotion and prevention of disease	IX - circulation	Population programmes
Stevens et al 1997	Research	Remotely controlled robots (laboratory)	6	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Stevens et al 1997	Research	Gene therapy for cystic fibrosis	6	Treatment and management of symptoms and disease	IV - endocrine	Regenerative medicine
Stevens et al 1997	Research	New anesthetic vapors	2	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	Magnetic resonance angiography	4	Diagnosis and monitoring of disease	IX - circulation	Diagnostic tests and imaging
Stevens et al 1997	Research	Digital radiography	4	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Stevens et al 1997	Research	Alendronate for osteoporosis	2	Treatment and management of symptoms and disease	XIII - musculoske letal	Drugs (not prophylactic vaccines)
Stevens et al 1997	Research	Continuous positive airways pressure	1	Treatment and management of symptoms and disease	X - respiratory	Non-surgical therapy

Stevens et al	Research	Evpanding motal	1	Treatment and	II concore	Daylisas and
	Research	Expanding metal stents for	1		II - cancers	Devices and
1997				management of		biomaterials
		esophageal cancer		symptoms and		
Ci e e e e e e e	D l.		4	disease		0
Stevens et al	Research	Community	1	Supporting	V - mental	Organisational
1997		placements for		patients receiving	health	programmes
		severe mental		care (designed to		
		illness		be used by		
				individuals)		
Stevens et al	Research	Fludarabine in	2	Treatment and	II - cancers	Drugs (not
1997		lymphomas and		management of		prophylactic
		chronic leukemias		symptoms and		vaccines)
				disease		
Stevens et al	Research	Combined therapy	2	Treatment and	1 -	Drugs (not
1997		for HIV/AIDS		management of	infections	prophylactic
				symptoms and		vaccines)
				disease		
Stevens et al	Research	Epilepsy surgery	1	Treatment and	VI -	Therapeutic
1997				management of	nervous	procedures
				symptoms and		
				disease		
Stevens et al	Research	Lipid-lowering	1	Health promotion	IX -	Drugs (not
1997		drugs for elevated		and prevention of	circulation	prophylactic
		cholesterol		disease		vaccines)
Stevens et al	Research	Repair of	4	Treatment and	IX -	Devices and
1997		abdominal aortic		management of	circulation	biomaterials
		aneurysm with		symptoms and		
		transfemoral		disease		
		endovasculate				
		(bifurcated) graft				
Stevens et al	Research	Intracytoplasmatic	2	Treatment and	XIV -	Therapeutic
1997		sperm injection		management of	genitourina	procedures
		- Form injection		symptoms and	ry	
				disease	.,	
Stevens et al	Research	Computed	2	Diagnosis and	Other -	Diagnostic tests
1997		tomography (CT)	_	monitoring of	generic	and imaging
1337		scan advances		disease	Berierie	
Stevens et al	Research	Voice activated	1	Supporting the	Other -	Organisational
1997		dictation	] _	provision of care	generic	programmes
		technology		and/or increasing	80	p. 68. a
				service efficiency		
Stevens et al	Research	Intra-arterial	1	Treatment and	IX -	Devices and
1997		metallic stents	=	management of	circulation	biomaterials
		camo sterito		symptoms and	2 24.44.011	2.5
				disease		
Tremblay and Yiu,	Policy	Hand-held robotic	14	Diagnosis and	Other -	Diagnostic tests
2006	planning	and remote		monitoring of	generic	and imaging
2000	Pidillillig	ultrasound		disease	School	and mideing
Tremblay and Yiu,	Policy	MRI guided	14	Diagnosis and	IX -	Diagnostic tests
2006	planning	catheterization		monitoring of	circulation	and imaging
2000	Pidillilli	Catheterization		disease	Circulation	and iniugilig
			L	นเวติวต		

Tremblay and Yiu,	Policy	Image-guided	14	Treatment and	Other -	Therapeutic
2006	planning	therapy and surgery and		management of symptoms and	generic	procedures
		robotics		disease		
Tremblay and Yiu, 2006	Policy planning	Computed Tomographic Colonography	14	Diagnosis and monitoring of disease	XI - GI tract, dental health	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Digital Tomosynthesis	14	Diagnosis and monitoring of	Other - generic	Diagnostic tests and imaging
		,		disease	J	
Tremblay and Yiu, 2006	Policy planning	Molecular-level imaging	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	More economical scanners with improved image processing	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Tremblay and Yiu, 2006	Policy planning	4D imaging	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Faster cycle time to capture an image and general reduction in scan times	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Tremblay and Yiu, 2006	Policy planning	Hybrid PET/CT increasingly replacing invasive procedures	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Stereotactic radio- surgery for early detection of coronary heart diseases	14	Diagnosis and monitoring of disease	IX - circulation	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Magnetic Resonance Guided Focused Ultrasound for Imaging of inflammation	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Wireless home- health monitoring	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	E-health diagnostic platform	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	Hand-held gamma camera	14	Diagnosis and monitoring of	Other - generic	Diagnostic tests and imaging

				disease		
Tremblay and Yiu, 2006	Policy planning	"one-stop" diagnosis and Therapeutic	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Organisational programmes
Tremblay and Yiu, 2006	Policy planning	customised hybrid systems for specific clinical situations	14	Unknown	Other - generic	Organisational programmes
Tremblay and Yiu, 2006	Policy planning	Near Infra-red Spectroscopy	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Spatially-resolved Spectroscopy	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Optical Coherence Tomography	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Capsule Endoscopy	14	Diagnosis and monitoring of disease	Other - generic	Devices and biomaterials
Tremblay and Yiu, 2006	Policy planning	Tele-echography	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	Tele-colposcopy	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	Electronic Nose	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	New contrast agents for Rubidium	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Hyperpolarised gases	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Terahertz waves	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006 Tremblay and Yiu,	Policy planning Policy	Microwaves, light spectrum  Hyperpolarised	14	Unknown  Diagnosis and	Other - generic Other -	Devices and biomaterials Diagnostic tests
2006	planning	imaging		monitoring of disease	generic	and imaging
Tremblay and Yiu, 2006	Policy planning	Specific advances in MRI, Ultrasound, Radiographyetc	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging

Tremblay and Yiu,	Policy	Reduction in use	14	Supporting the	Other -	Organisational
2006	planning	of invasive diagnostic procedures		provision of care and/or increasing service efficiency	generic	programmes
Tremblay and Yiu, 2006	Policy planning	Diagnosis of kidney disorders without renal biopsy	14	Diagnosis and monitoring of disease	XIV - genitourina ry	Unknown
Tremblay and Yiu, 2006	Policy planning	Ex vivo molecular- computer diagnosis	14	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	Smart-drug delivery systems	14	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
Tremblay and Yiu, 2006	Policy planning	Polymer- encapsulated, bioconjugated quantum dots	9	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Patient accessed universal health records	4	Supporting the provision of care and/or increasing service efficiency	Other - generic	Organisational programmes
Tremblay and Yiu, 2006	Policy planning	In silico-in vivo integration (lab on-a-chip)	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Wide deployment of non-invasive technologies and biosensors	9	Supporting the provision of care and/or increasing service efficiency	Other - generic	Devices and biomaterials
Tremblay and Yiu, 2006	Policy planning	Direct consumer access to diagnostic tests	6	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Organisational programmes
Tremblay and Yiu, 2006	Policy planning	Molecular imaging with single molecular pecision	9	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	diagnostic testing throughout the care pathway	7	Supporting the provision of care and/or increasing service efficiency	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Neuro-imaging at cellular level of brain processes (thoughts)	14	Diagnosis and monitoring of disease	VI - nervous	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Molecular- computers used to design smart therapies	14	Other	Other - generic	Drugs (not prophylactic vaccines)

Tremblay and Yiu, 2006	Policy planning	Remote internet diagnosis based on data received from patient's home	9	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	Molecular diagnosis	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	diagnostic -guided therapy for individualised medicine	14	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Tremblay and Yiu, 2006	Policy planning	Computer- assisted diagnosis with pattern recognition	14	Diagnosis and monitoring of disease	Other - generic	IT systems, eHealth and mHealth
Tremblay and Yiu, 2006	Policy planning	Self-propelled micro-machines for diagnosis and Therapeutic	9	Unknown	Other - generic	Devices and biomaterials
Tremblay and Yiu, 2006	Policy planning	diagnostic bio- chip for cancer	9	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Investigation of thrombosis and vascular pathology using 3D tomography with remote controlled microinstruments	14	Diagnosis and monitoring of disease	IX - circulation	Devices and biomaterials
Tremblay and Yiu, 2006	Policy planning	Personal care nurse-robots	12	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Medical equipment
Tremblay and Yiu, 2006	Policy planning	Functional combination of targeting and imaging	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Tremblay and Yiu, 2006	Policy planning	Intelligent and context sensitive clinical systems	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Organisational programmes
Tremblay and Yiu, 2006	Policy planning	Personal access to genomic information	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Unknown
Tremblay and Yiu, 2006	Policy planning	Development of effective gene	9	Treatment and management of	Other - generic	Regenerative medicine

		therapies		symptoms and disease		
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of scientific guidelines for adult-disease-preventing lifestyles (nutrition, rest and exercise)	9	Health promotion and prevention of disease	Other - generic	Organisational programmes
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of chemotherapy that brings complete remission to digestive organ cancer with low drug-responsiveness	18	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of techniques to overcome the drug resistance of malignant tumours	16	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of drugs that cure viral liver disease	13	Treatment and management of symptoms and disease	XI - GI tract, dental health	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of biological and immunological therapy effective for cancer	14	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Development of effective methods of preventing Alzheimer's disease	16	Health promotion and prevention of disease	V - mental health	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Possible to cure allergic diseases	21	Treatment and management of symptoms and disease	III - blood	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Development of an HIV vaccine	10	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of gene therapy against malignant tumors	17	Treatment and management of symptoms and disease	II - cancers	Regenerative medicine

Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of prevention methods for the contraction of diabetic complications	11	Health promotion and prevention of disease	IV - endocrine	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of anti-AIDS therapy	12	Treatment and management of symptoms and disease	I - infections	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of an early cancer diagnosis technique based on biochemical examination	10	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of a technique to eliminate viruses from blood	12	Treatment and management of symptoms and disease	I - infections	Therapeutic procedures
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of prevention methods for stress-induced mental disorders	14	Health promotion and prevention of disease	V - mental health	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a method to quantitatively assess the level of aging (biological age) in relation to chronological age.	9	Diagnosis and monitoring of disease	Other - generic	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a preventive measure against diabetic complications.	14	Health promotion and prevention of disease	IV - endocrine	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of presbyopia prevention methods	29	Health promotion and prevention of disease	VII - eye	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of a laser-applied tooth decay treatment method	14	Treatment and management of symptoms and disease	XI - GI tract, dental health	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread method of prevention against a premature delivery through	8	Health promotion and prevention of disease	XV - pregnancy	Organisational programmes

		the progression of management system of fetal				
		information.				
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of the prevention against congenital anomaly originating in the embryonic or fetal period.	19	Health promotion and prevention of disease	XV - pregnancy	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of preventive measure for cerebral palsy	19	Health promotion and prevention of disease	VI - nervous	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of a cancer spread diagnosis technique based on 3-D imaging.	7	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of a cancer risk assessment technique based on genetic analysis.	11	Diagnosis and monitoring of disease	II - cancers	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of against of cancer cells drug sensitivity measurement method.	9	Unknown	II - cancers	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of automatic testing equipment for cancer cytodiagnosis.	9	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of classification and stage determination of schizophrenia based on diagnostic imaging.	24	Diagnosis and monitoring of disease	V - mental health	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of diagnosing methods for determining the level and spread of arteriosclerosis	9	Diagnosis and monitoring of disease	IX - circulation	Diagnostic tests and imaging

		focused by a non- invasive process				
Science & Technology Foresight survey Japan 1997	Policy planning	Establishment of a correct diagnostic measure for kidney diseases without renal biopsy.	19	Diagnosis and monitoring of disease	XIV - genitourina ry	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Development of a capsule-type total gastro-intestinal tract monitoring system.	6	Diagnosis and monitoring of disease	XI - GI tract, dental health	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of specialist-level medical diagnosis assistance systems.	9	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Science & Technology Foresight survey Japan 1997	Policy planning	Development of non-invasive cell-level diagnostic imaging.	8	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a non-invasive technique to obtain blood biochemical examination data using body surface sensors.	9	Diagnosis and monitoring of disease	III - blood	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a rapid diagnostic method for rejection in organ and tissue transplantation.	6	Diagnosis and monitoring of disease	III - blood	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of malaria vaccines.	10	Health promotion and prevention of disease	I - infections	Prophylactic vaccines
Science & Technology Foresight survey Japan 1997	Policy planning	Development of an effective insulin that can be administered orally.	16	Treatment and management of symptoms and disease	IV - endocrine	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of gene therapy for diabetes.	16	Treatment and management of symptoms and disease	IV - endocrine	Regenerative medicine

Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of gene therapy for familial hypercholesterole mia.	14	Treatment and management of symptoms and disease	IX - circulation	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of radiosensitizers effective in cancer treatment.	8	Treatment and management of symptoms and disease	II - cancers	Therapeutic procedures
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of heavy particle against cancer	14	Treatment and management of symptoms and disease	II - cancers	Non-surgical therapy
Science & Technology Foresight survey Japan 1997	Policy planning	Development of a technique to cause drug delivery to targeted sites in the brain.	19	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a safe pain control method without side effects	12	Treatment and management of symptoms and disease	Other - generic	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of gene therapy for muscular dystrophy.	24	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of effective treatment for amyotrophic lateral sclerosis.	31	Treatment and management of symptoms and disease	VI - nervous	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of artificial muscles for limbs.	21	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a technique to induce the differentiation of fibroblasts into cardiac muscle and its application to the treatment of myocardial infarction.	20	Treatment and management of symptoms and disease	IX - circulation	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of hybrid-type artificial endocrine organs in which living	11	Treatment and management of symptoms and disease	IV - endocrine	Regenerative medicine

		cells and artificial objects coexist.				
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of functional blood purifiers that selectively remove specified components from blood	19	Treatment and management of symptoms and disease	III - blood	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of artificial hemoglobin as a red blood cell substitute.	15	Treatment and management of symptoms and disease	III - blood	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of fully implanted artificial heart	14	Treatment and management of symptoms and disease	IX - circulation	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of fully implanted artificial lungs.	29	Treatment and management of symptoms and disease	X - respiratory	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of fully implanted artificial kidneys	26	Treatment and management of symptoms and disease	XIV - genitourina ry	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of fully implanted artificial pancreas	12	Treatment and management of symptoms and disease	XI - GI tract, dental health	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of prevention and treatment methods for tooth decay and periodontitis to ensure the retention of 20 or more teeth at 80 year of age	14	Health promotion and prevention of disease	XI - GI tract, dental health	Population programmes
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of a technique to store, cultivate and transplant one's own tissues.	15	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of implanted bladder control devices	12	Treatment and management of symptoms and disease	XIV - genitourina ry	Devices and biomaterials

Science &	Policy	Practical use of	19	Treatment and	Other -	Regenerative
Technology	planning	gene therapy for	13	management of	generic	medicine
Foresight survey	planning	genetic disorders		symptoms and	generic	medicine
Japan 1997		genetic disorders		disease		
Science &	Policy	Availability of	24	Treatment and	Other -	Regenerative
Technology	planning	genetherapy	24	management of		medicine
• • • • • • • • • • • • • • • • • • • •	piaming	based on oral		_	generic	medicine
Foresight survey				symptoms and		
Japan 1997	Dalian	delivery	24	disease	Other	The area and the
Science &	Policy	Practical use of	21	Treatment and	Other -	Therapeutic
Technology	planning	heterogeneous		management of	generic	procedures
Foresight survey		organ		symptoms and		
Japan 1997		transplantation as		disease		
		means of				
6.1	D. II.	treatment.	4.2	6	Other	0
Science &	Policy	Widespread use	12	Supporting the	Other -	Organisational
Technology	planning	of a worldwide		provision of care	generic	programmes
Foresight survey		organ supply		and/or increasing		
Japan 1997		system	_	service efficiency		
Science &	Policy	Development of a	6	Treatment and	Other -	Non-surgical
Technology	planning	partial tissue		management of	generic	therapy
Foresight survey		destruction		symptoms and		
Japan 1997		method non-		disease		
		invasive to the				
		living body.				
Science &	Policy	Practical use of	14	Rehabilitation	VIII - ear	Devices and
Technology	planning	implanted				biomaterials
Foresight survey		artificial cochleas				
Japan 1997		effective for both				
		conductive				
		hearing loss and				
		perceptive				
		hearing loss.				
Science &	Policy	Development of a	21	Supporting	V - mental	Devices and
Technology	planning	device to sense		patients receiving	health	biomaterials
Foresight survey		the needs of		care (designed to		
Japan 1997		demented aged		be used by		
		people.		individuals)		
Science &	Policy	Development of	14	Rehabilitation	XXI -	Devices and
Technology	planning	controlling			screening,	biomaterials
Foresight survey		devices which			rehab	
Japan 1997		help the				
		cooperative				
		muscular actions				
		enabling object-				
		oriented				
		movement.				
Science &	Policy	Widespread use	11	Rehabilitation	XXI -	Devices and
Technology	planning	of artificial legs			screening,	biomaterials
Foresight survey		featuring a small			rehab	
Japan 1997		power source and				
		computer control.				

Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a blood cell production and supply technique based on industrial-scale cultivation.	15	Treatment and management of symptoms and disease	III - blood	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of systems for monitoring health condition and providing information for an appropriate diagnosis at home in event of accident or diseases.	11	Supporting patients receiving care (designed to be used by individuals)	XIX - injury	IT systems, eHealth and mHealth
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of portable conversational speech interpretation systems.	24	Unknown	Other - generic	IT systems, eHealth and mHealth
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of robots that care for people with severe physical and mental disabilities.	12	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Medical equipment
Science & Technology Foresight survey Japan 1997	Policy planning	Advancements in patient and hospital information management, leading to a reduction in waiting time at Japanese hospitals to 15 minutes or less.	7	Supporting the provision of care and/or increasing service efficiency	Other - generic	Organisational programmes
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use in Japan of an ID card system that thoroughly covers an individual's health conditions and medical data.	9	Supporting the provision of care and/or increasing service efficiency	Other - generic	Organisational programmes
Science & Technology Foresight survey	Policy planning	Elucidation of the biological clock, leading to drug	9	Supporting patients receiving care (designed to	Other - generic	Unknown

Japan 1997		administration that takes it into consideration		be used by individuals)		
Science & Technology Foresight survey Japan 1997	Policy planning	Practical application of the production of artificial cells with organ characteristics.	29	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of anti-AIDS therapy	12	Treatment and management of symptoms and disease	I - infections	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of a rapid diagnostic method for rejection in organ and tissue transplantation	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Development of anti-cancer agents which target the manifestation functions of cancer genes	10	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Utilization of information about the gene structure of each individual patient in diagnosis and treatment	16	Diagnosis and monitoring of disease	Other - generic	Organisational programmes
Science & Technology Foresight survey Japan 1997	Policy planning	Development of technology to regenerate organs or individuals from separated animal cells	20	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of methods for directly determining DNA sequences by physical means such as X-rays.	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Science & Technology Foresight survey Japan 1997	Policy planning	Control of signal transduction in the carcinogenesis of cells, and widespread use of treatment	20	Treatment and management of symptoms and disease	II - cancers	Drugs (not prophylactic vaccines)

		methods for dysdifferentiating carcinogenic cells.				
Science & Technology Foresight survey Japan 1997	Policy planning	Complete understanding of the factors contributing to stem cell multiplication, and widespread use of the practice of multiplying stem cells, as necessary, in test tubes and using them for treatment purpose	15	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of technology capable of synthesizing living cells by using only artificially produced chemical compounds.	31	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of elementary particle beam technology in genetic engineering.	19	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of drugs capable of preventing the occurrence of certain types of cancer.	11	Health promotion and prevention of disease	II - cancers	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of effective means to prevent metastasis of cancer.	14	Treatment and management of symptoms and disease	II - cancers	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of technologies for long-term (semi-permanent) culturing and preservation of	19	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine

		organs.				
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of artificial organs (pancreases, kidneys, livers, etc.) incorporating human cells and tissues	14	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of an entirely implantable artificial kidney.	18	Treatment and management of symptoms and disease	XIV - genitourina ry	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Development of an artificial cornea, allowing the visually impaired to regain their sight.	25	Treatment and management of symptoms and disease	VII - eye	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Development of artificial muscle elements.	21	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Science & Technology Foresight survey Japan 1997	Policy planning	Establishment of interface technology between neural information and artificial organism structures.	25	Treatment and management of symptoms and disease	VI - nervous	Medical equipment
Science & Technology Foresight survey Japan 1997	Policy planning	Development of neural-computers with new logic structures modeled on brain functions.	24	Unknown	VI - nervous	IT systems, eHealth and mHealth
Science & Technology Foresight survey Japan 1997	Policy planning	Development of interfaces enabling direct linkage between the computer and the brain.	21	Treatment and management of symptoms and disease	XXI - screening, rehab	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Development of electric circuits with similar selforganization and self-restoration functions as neural networks.	14	Treatment and management of symptoms and disease	VI - nervous	Devices and biomaterials

Science & Technology Foresight survey Japan 1997	Policy planning	Development of diagnostic and medical treatment micromachines capable of traveling on their own inside organisms (body cavity organs).	24	Diagnosis and monitoring of disease	Other - generic	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of remote surgery systems utilizing virtual reality technology.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of vicarious experience devices (using virtual reality technology) which allow bed-ridden patients to take vacations, etc.	9	Rehabilitation	XXI - screening, rehab	IT systems, eHealth and mHealth
Science & Technology Foresight survey Japan 1997	Policy planning	Widespread use of methods for controlling the immune system locally	14	Treatment and management of symptoms and disease	III - blood	Unknown
Science & Technology Foresight survey Japan 1997	Policy planning	Development of effective Therapeutic for amyotrophic lateral sclerosis	21	Treatment and management of symptoms and disease	VI - nervous	Drugs (not prophylactic vaccines)
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of batteries of artificial organs implanted in the living body	17	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Development of artificial liver (external devices supporting liver functions) usable on a long-term, continuous basis	19	Treatment and management of symptoms and disease	XI - GI tract, dental health	Devices and biomaterials
Science & Technology Foresight survey Japan 1997	Policy planning	Practical use of heterogeneous organ transplantation as means of Therapeutic	19	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures

Science &	Policy	Development of	24	Rehabilitation	VII - eye	Devices and
Technology	planning	artificial eyes				biomaterials
Foresight survey		featuring				
Japan 1997		electronic circuitry				
		that can be				
		connected to				
		nerve and brain				
		cells				
Science &	Policy	Development of	29	Rehabilitation	VI -	Therapeutic
Technology	planning	methods for			nervous	procedures
Foresight survey		recombining				
Japan 1997		disconnected				
		central nerves			0.1	
Loveridge et al	Policy	Practical use of	21	Diagnosis and	Other -	Diagnostic tests
1998	planning	directly visualising		monitoring of	generic	and imaging
		molecular		disease		
		structure at an				
		atomic level (e.g.				
Loveridge et al	Policy	ultramicroscopy) At least 3	21	Treatment and	Other -	Devices and
1998	planning	common diseases	21	management of		biomaterials
1990	planning	will be treated by		symptoms and	generic	Diomaterials
		portable or		disease		
		implanted		uisease		
		systems that				
		combine				
		individually				
		tailored drug				
		delivery with				
		automatic				
		feedback control				
		from a devices				
		continuously				
		monitoring the				
		condition (e.g.				
		diabetes control)				
Loveridge et al	Policy	Over-the-counter	21	Supporting	Other -	IT systems, eHealth
1998	planning	nucleicacid-based		patients receiving	generic	and mHealth
		tests suitable for		care (designed to		
		self-		be used by		
		administration		individuals)		
		become available				
		for the first time				
Loveridge et al	Policy	Results of more	21	Diagnosis and	Other -	Diagnostic tests
1998	planning	than 50% of all		monitoring of	generic	and imaging
		types of		disease		
		diagnostic tests				
		are available at				
		the point of need				
		within one hour				

Loveridge et al 1998	Policy planning	Widespread use of real time 3-D high resolutiom imaging of physiological and metabolic functions	21	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Loveridge et al 1998	Policy planning	First practical use of non-invasive spectroscopy for in situ chemical pathology	21	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Loveridge et al 1998	Policy planning	Practical use of biosensors in a wide range of medical manufacturing and environmental applications	21	Unknown	Other - generic	Devices and biomaterials
Loveridge et al 1998	Policy planning	All common single genes diseases can be treated successfully by gene theraby	21	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Loveridge et al 1998	Policy planning	Practical use of gene therapy is extended to the treatment of 30% of major life threatening diseases	21	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Loveridge et al 1998	Policy planning	Nucleic acid based diagnostic techniques account for 10% of all diagnostic e work load	21	Diagnosis and monitoring of disease	Other - generic	Organisational programmes
Loveridge et al 1998	Policy planning	First practical use of therapies based on purpose designed non-peptide molecules which mimic the activity of peptides.	21	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Loveridge et al 1998	Policy planning	Widespread use of polypeptide drugs which are delivered orally and targeted to	21	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)

		specific tissues				
Loveridge et al 1998	Policy planning	Widespread use of cosmaceuticals with scientifically	21	Health promotion and prevention of disease	XII - skin	Drugs (not prophylactic vaccines)
		proven effectiveness to treat the sypmtoms of skin				
		ageing (e.g. wrinkles)				
Loveridge et al 1998	Policy planning	Widespread use of improved technologies for	21	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
		early diagnosis increases the 5-		uisease		
		year survival rate of cancer patients by 50%				
Loveridge et al 1998	Policy planning	Practical use of drugs modulating cellular systems to	21	Treatment and management of symptoms and	II - cancers	Drugs (not prophylactic vaccines)
		treat cancer		disease		·
Loveridge et al 1998	Policy planning	Widespread use of nutritional supplements or special diets	21	Health promotion and prevention of disease	II - cancers	Population programmes
		based on an understading of the role of				
		nutrients such as anti-oxidants in cancer prevention				
Loveridge et al	Policy	Practical use of	21	Treatment and	II - cancers	Drugs (not
1998	planning	substances that contain rather		management of symptoms and		prophylactic vaccines)
		eleminate cancer (e.g. use agents		disease		
		that control metastasis)				
Loveridge et al 1998	Policy planning	New methods of treating arterial	21	Treatment and management of	IX - circulation	Unknown
		occlusion and myocardial		symptoms and disease		
		infarction dramatically				
		reduce morbidity from				
		cardiovascular diseases in 40-50				
		age group				

Loveridge et al	Policy	50% of the UK	21	Health promotion	IX -	Population
1998	planning	population		and prevention of	circulation	programmes
		receive individual		disease		
		risk assessment				
		for cardiovascular				
		disease based on				
		genetic screening				
		and lifestyle				
		measures				
Loveridge et al	Policy	Understanding	21	Treatment and	III - blood	Therapeutic
1998	planning	the immune		management of		procedures
		system is		symptoms and		
		sufficietly		disease		
		developed to				
		allow routine				
		transplantation				
		without the use of				
		immuno-				
		suupression				
Loveridge et al	Policy	Practical use of	21	Treatment and	Other -	Regenerative
1998	planning	xenotransplantati		management of	generic	medicine
		on of organs from		symptoms and		
		animals to human		disease		
Loveridge et al	Policy	Incidence of each	21	Health promotion	1 -	Prophylactic
1998	planning	of the 3 major		and prevention of	infections	vaccines
		viral diseases is		disease		
		reduced by 90%				
		by new vaccines				
		or drug				
		development				
Loveridge et al	Policy	Practical use of	21	Health promotion	1-	Prophylactic
1998	planning	technologies for		and prevention of	infections	vaccines
		oral		disease		
		administration of				
		multi-valent				
		vaccines for the				
		most important				
		childhood				
Lavariales at al	Delim	illnesses	21	Haalth	1	Duombo de ette
Loveridge et al	Policy	Widespread	21	Health promotion	-	Prophylactic
1998	planning	introduction of		and prevention of	infections	vaccines
		malaria vaccine		disease		
		reduces the worldwide				
		incidence of the				
Loveridge et al	Policy	diseases by 50% First effective	21	Health promotion	1-	Prophylactic
1998	planning	vaccine of HIV	21	and prevention of	infections	vaccines
1330	higininig	becomes available		disease	miections	vaccines
Loveridge et al	Policy	Development of	21	Treatment and	V - mental	Drugs (not
1998	planning	drugs with proven		management of	health	prophylactic
1330	hiailillig	urugs with proven		management of	HEAILII	propriyiactic

		efficacy for enhancing cognitive performance		symptoms and disease		vaccines)
Loveridge et al 1998	Policy planning	50% of patients presenting with mental illness such as schizphrenia and depression are diagnosed using objective genetic, biochemical or biophysical tests	21	Diagnosis and monitoring of disease	V - mental health	Diagnostic tests and imaging
Loveridge et al 1998	Policy planning	50% of surgical interventions carried out by minimum-access technique	21	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Loveridge et al 1998	Policy planning	10% of surgical interventions are carried out by robotic techniques	21	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Loveridge et al 1998	Policy planning	Development of biocompatible materials for implants which elicit the required host response (e.g. non-thrombogenic or stimulation of host repair mechanisms).	21	Treatment and management of symptoms and disease	Other - generic	Devices and biomaterials
Loveridge et al 1998	Policy planning	Widespread use for skin replacemt and/or repair of reliable products based on tissue engineering	21	Treatment and management of symptoms and disease	XII - skin	Regenerative medicine
Loveridge et al 1998	Policy planning	Practical availability for regular clinical use of functional human organ tissue for kidney, liver or pancreas	21	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
Loveridge et al 1998	Policy planning	Widespread use of non-surgical (eg. by	21	Health promotion and prevention of disease	XXI - screening, rehab	Drugs (not prophylactic vaccines)

Loveridge et al 1998	Policy planning	vaccination) single application contraception offering lifetime control 50% of contraception involving pharmacological or vaccine methods resides	21	Health promotion and prevention of disease	XXI - screening, rehab	Drugs (not prophylactic vaccines)
Loveridge et al 1998	Policy planning	with men 50% of diagnostic and treatment decisions involve use of expert systems	21	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Loveridge et al 1998	Policy planning	20% of time spent by doctors in primary care screeing is replaced by patient interaction with experts systems	21	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Loveridge et al 1998	Policy planning	Practical use of remote electronic systems which substitute human labour in montoring the physical parameter of elderly and people with disability in the community	21	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Loveridge et al 1998	Policy planning	Widespread use of unified and standardised electronic data collection systems and data informats for medical records	21	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Loveridge et al 1998	Policy planning	At least 50% of health care centres (hospitals, clinic,etc) are connected to national information	21	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth

Loveridge et al 1998	Policy planning	electronic networks for patient records and information on diagnosis, treatment and outcome Widespread use in health care of electronic information systems which span existing professional and organisational	21	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
		boundries (health, social service, housing etc)	24		204	
Loveridge et al 1998	Policy planning	Improved understanding of the role of gene- environment interactions in causing common structural birth birth defects (e.g. cleft palate) permits the implementation of primary preventable programmes	21	Health promotion and prevention of disease	XXI - screening, rehab	Population programmes
Loveridge et al 1998	Policy planning	Understanding how environmental factors encountered in early life cause adult disease leads to national standards for diet and lifestyle in pre-natal and early life	21	Health promotion and prevention of disease	XXI - screening, rehab	Population programmes
Loveridge et al 1998	Policy planning	Widespread use of financial inducements by national and private health insurers or similar bodies to adopt	21	Health promotion and prevention of disease	Other - generic	Organisational programmes

		healthier lifestyle or diets				
Loveridge et al 1998	Policy planning	The causes of the rising prevalence of asthma are elucidated and action based on this knowledge leads to a 50% reduction in the incidence of severe disease	21	Health promotion and prevention of disease	X - respiratory	Population programmes
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	X-ray replaced by Magnetic Resonance Imaging (MRI)	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	operating theatre of 2010 will be built with an ultraopen MRI system with parallel ultrasound facilities and complete optical capability	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Endoscopes will reduce in size as fibres, lenses and electronic sensors get smaller,	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Devices and biomaterials
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	CCD image sensors have the ability to see in both ultra-violet and near infrared.	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	New magnetic sensing technologies will detect the configuration of the endoscope and accessory devices inside the patient.	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Devices and biomaterials

Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Auto focus and zoom optical systems will be interfaced with 30 to take the endoscope imaging capability beyond what is currently possible with human vision.	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	High resolution ultrasound in closer proximity to the tissue and structures to be studied	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Laser induced fluorescence imaging systems for diagnosis of early malignant changes, monitoring and therapy will become available.	14	Diagnosis and monitoring of disease	II - cancers	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Near infra-red spectroscopy, for looking at tissue oxygenation state	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Confocal, or other optical, ultrasonic or magnetic resonance microscopy, for on-line histology of bulk samples	14	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Minimal Access Surgery is likely to account for as much as 75% of surgical procedures	14	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Robotic camera holders are likely to become routine in laparoscopic procedures.	14	Treatment and management of symptoms and disease	Other - generic	Medical equipment

Operating theatre of the year 2010; Department of Trade and Industry  Operating theatre	Policy planning Policy	The operating table's control system and the robotics system could become integrated in the future operating table.  Ability to ventilate	14	Supporting the provision of care and/or increasing service efficiency  Treatment and	Other - generic	Medical equipment  Non-surgical
of the year 2010; Department of Trade and Industry	planning	all patients from neonates to adults		management of symptoms and disease	respiratory	therapy
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Control handsets will incorporate dot matrix displays which will give the operator information about the condition of the table, position of the top and warnings about possible hazards	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	The operating table may have a built-in patient temperature regulation system.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Connection between the Operating Room and the Anaesthetic machine in the Control Room will be via the Anaesthetist in the Operating Room.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	The Anaesthetic machine will incorporate both inhalation agent vaporisation and multi-drug infusion systems These devices will be electronically integrated into the monitoring	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment

	ı	1	1	Τ	ı	1
		and information management and anaesthetic record keeping system so that vaporiser concentration settings and				
		infusion rates will be continuously recorded				
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Mechanical flow- meters will be replaced by electronic gas mixing systems	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Patient monitoring will be very simple and intuitive probably touch screen and quite possibly voice activation.	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Monitors will also network into central areas outside the operating theatre so that, for example, anaesthetics being delivered by less experienced staff can be monitored remotely.	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	The operation room will capture the data from one or perhaps two small 'wireless' sensors placed on the body that will provide pulse oxyimetry CO2, ECG and other key parameter data and then transmit them to the monitor via radio or IR technology.	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth

Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Patient will be equipped with a belt (or other suitable garment) into which all monitoring and feed lines will be terminated, and which will include significant active capability. Drip and other lines will also be terminated in the belt	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Devices and biomaterials
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Patient can be "plugged" into electrical support, monitoring and stimulation as well as fluid and chemical agents using a single connector to facilitate transfer of patient from one ward to another or from the operation theatre	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Operation lamp will be replaced by a better light source	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Automatic control of light pattern in the operation theatre	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	The operating lamp of the future is likely to use much more electronics to accurately control the voltage, dimming, focus, tracking and to limit maximum light intensity to	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment

		safe levels.				
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	The operating lamps of the future will be sealed for easy disinfection	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Telemedicine	14	Unknown	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Telemonitoring	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Teleconsultation	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Telesurgery for demonstartion or teaching	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Minimal access surgery (MAS)	14	Treatment and management of symptoms and disease	Other - generic	Therapeutic procedures
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Systems in which as much of the patient's own blood is recovered and recycled as possible.	14	Treatment and management of symptoms and disease	III - blood	Non-surgical therapy
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Use of flexible endoscope technology to allow surgeons to see around and behind structures, giving the surgeon greater access and the patient a greater degree of safety.	14	Treatment and management of symptoms and disease	XI - GI tract, dental health	Devices and biomaterials

Operating theatre of the year 2010; Department of Trade and Industry  Operating theatre	Policy planning  Policy	A move away from the use of X-rays and image intensification towards more mobile methods of MRI scanning.  Developments in	14	Diagnosis and monitoring of disease  Treatment and	Other - generic	Diagnostic tests and imaging  Therapeutic
of the year 2010; Department of Trade and Industry	planning	the use of laser and particularly electrosurgery	14	management of symptoms and disease	generic	procedures
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Use of robotics and head up display allowing surgeon sitting in a control room rather than being in the theatre with the patient	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Coding will be used to associate patient, operating procedure (and so appropriate tools and drugs), support facilities and to generate automatic records of usage.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Tools and devices for a procedure will be located in a carousel analogous to that for a computer numerically controlled machine tool. This will allow the surgeon to present his tool holder to it, have the old tool extracted and a new one inserted.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Robots will be used as transport vehicles both within the operating room	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment

		and for the surrounding support areas				
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Robots will carry out very precise procedures controlled by the surgeon from a distance,	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Joint replacement be performed robotically	14	Treatment and management of symptoms and disease	XIII - musculoske letal	Therapeutic procedures
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	The operation theatre may be controlled by a robot "software" box th at will respond to voice recognition of the surgeon and change factors such as the heating of the theatre, the lighting and position of the table	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	A robot would be able to transfer sterile instrument trays from a central sterile store to the surgeon at the operating table.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Transport Robots could be used in the supply and disposal functions outside the operating room within the operating suite	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Robots will be used in moving patients from ward to theatre areas (to replace the use of porters)	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment

Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Using dedicated robot trucks similar to the supply trucks, waste could be collected on a regular basis from each theatre and taken to an automatic local waste reduction/disposal facility adjacent to the theatre suite.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Disposal of hospital material could be performed on site with the use of machines such as "needle eaters"	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Bulky X-Ray machines will probably be a thing of the past and replaced by computerised radiology	14	Diagnosis and monitoring of disease	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	A central control room, with visual links to each theatre served, could house all of the equipment.	14	Supporting the provision of care and/or increasing service efficiency	Other - generic	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	All theatres could be designed with ultra-clean ventilation systems or an adapted containment system to reduce the risk of the spread of infection	14	Health promotion and prevention of disease	I - infections	Medical equipment
Operating theatre of the year 2010; Department of Trade and Industry	Policy planning	Patients identification bracelets could be coded and bar checked as they moved through	14	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Medical equipment

Operating theatre	Policy	the system so that their progress could be monitored at all times Automated	14	Supporting the	Other -	Medical equipment
of the year 2010; Department of Trade and Industry	planning	trolleys and doors that can be electronically controlled by robots	14	provision of care and/or increasing service efficiency	generic	Medical equipment
UK technology and innovation futures for the 2020s, 2010	Policy planning	Further development of 3D imaging techniques.	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	Fluorescenceassist ed Resection and Exploration (FLARE) technologies, which combine both visible light imaging with near-infra red imaging of fluorescent biomarkers, can detect particular pathologies associated with tumours without the need for biopsy	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	Colour X-ray or TEDDI imaging can be used to biopsy tissues by utilising scattered X-rays to build a spatially-resolved picture that can distinguish between different materials.	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	In vivo neuroimaging, both at the tissue and cellular level	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
UK technology and innovation futures for the	Policy planning	Brain imaging techniques such as functional	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging

2020s, 2010		magnetic resonance				
		imaging (fMRI)				
UK technology and innovation futures for the 2020s, 2010	Policy planning	Lab-on-a-Chip (LOC) devices integrate and scale-down biomedical and	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
		other analytical laboratory functions and processes to a miniaturised chip format.				
UK technology	Policy	Nucleic acid	10	Diagnosis and	Other -	Diagnostic tests
and innovation	planning	probes and		monitoring of	generic	and imaging
futures for the		diagnostic		disease		
2020s, 2010		microarray				
		systems can				
		detect the nucleic				
		acid sequence or sequences that				
		identify a specific				
		infectious disease				
		agent, human				
		genetic disease or				
		individual (DNA				
		profiling).				
UK technology and innovation	Policy	A new focus on	10	Treatment and	Other -	Regenerative medicine
futures for the	planning	single-stranded DNA, micro RNA		management of symptoms and	generic	medicine
2020s, 2010		(miRNA) and		disease		
		double-stranded				
		RNA (dsRNA)				
		technologies as				
		therapeutics may				
		lead to clinically-				
		approved interventions for				
		gene therapy and				
		treatment of				
		medical disease.				
UK technology	Policy	RNA interference	10	Treatment and	Other -	Regenerative
and innovation	planning	(RNAi) may lead		management of	generic	medicine
futures for the		to new		symptoms and disease		
2020s, 2010 UK technology	Policy	treatments. Viruses, bacteria	10	Treatment and	Other -	Regenerative
and innovation	planning	or yeasts may be	10	management of	generic	medicine
futures for the	P.G.IIIIIB	able to act as		symptoms and	00	
2020s, 2010		carriers for new		disease		
		sequences of DNA				

UK technology and innovation futures for the 2020s, 2010	Policy planning	Increased understanding of individual sensitivities to drugs	10	Diagnosis and monitoring of disease	III - blood	Drugs (not prophylactic vaccines)
UK technology and innovation futures for the 2020s, 2010	Policy planning	DNA vaccines for AIDS, malaria, hepatitis B and certain cancers may be available within 10 years	10	Health promotion and prevention of disease	Other - generic	Prophylactic vaccines
UK technology and innovation futures for the 2020s, 2010	Policy planning	New treatments for for neurodegenerativ e conditions such as dementia.	10	Treatment and management of symptoms and disease	VI - nervous	Unknown
UK technology and innovation futures for the 2020s, 2010	Policy planning	'Cognition enhancers'; substances that enhance the performance of our brain in specific ways, such as improving short-term memory and increasing our speed of thought enhancement through lifestyle drugs may will become the norm.	10	Treatment and management of symptoms and disease	VI - nervous	Drugs (not prophylactic vaccines)
UK technology and innovation futures for the 2020s, 2010	Policy planning	'Emoticeuticals', drugs that act by changing hormone levels in the body, may mediate our responses in our private lives and work.	10	Treatment and management of symptoms and disease	V - mental health	Drugs (not prophylactic vaccines)
UK technology and innovation futures for the 2020s, 2010	Policy planning	Sensoceuticals' might enhance pleasure by restoring or accentuating the senses.	10	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
UK technology and innovation futures for the 2020s, 2010	Policy planning	The advent of a drug that mimics the positive effects of alcohol	10	Health promotion and prevention of disease	V - mental health	Drugs (not prophylactic vaccines)

		with none of its drawbacks.				
UK technology and innovation futures for the 2020s, 2010	Policy planning	Stem cells replacing malfunctioning liver cells or even growing entire livers to replace diseased ones	10	Treatment and management of symptoms and disease	XI - GI tract, dental health	Regenerative medicine
UK technology and innovation futures for the 2020s, 2010	Policy planning	Stem cells giving new neurons to those with brain damage	10	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
UK technology and innovation futures for the 2020s, 2010	Policy planning	Stem cells giving new heart cells to those with heart disease	10	Treatment and management of symptoms and disease	IX - circulation	Regenerative medicine
UK technology and innovation futures for the 2020s, 2010	Policy planning	Stem cells giving therapies for Parkinson's and Alzheimer's diseases	10	Treatment and management of symptoms and disease	VI - nervous	Regenerative medicine
UK technology and innovation futures for the 2020s, 2010	Policy planning	Stem cells giving therapies for spinal cord injury, stroke, cancer, burns, cardiovascular disease, diabetes, osteoarthritis and rheumatoid arthritis; as well as furnishing an endless supply of red blood cells for transfusions.	10	Treatment and management of symptoms and disease	Other - generic	Regenerative medicine
UK technology and innovation futures for the 2020s, 2010	Policy planning	Development of a cheap anti-malarial drug.	10	Treatment and management of symptoms and disease	I - infections	Drugs (not prophylactic vaccines)
UK technology and innovation futures for the 2020s, 2010	Policy planning	Programming a bacterium or virus that can identify malignant cells and can deliver a therapeutic agent could have major benefits for treating cancer and similar illnesses	10	Treatment and management of symptoms and disease	II - cancers	Regenerative medicine

UK technology	Policy	Stratified	10	Diagnosis and	Other -	Diagnostic tests
and innovation futures for the 2020s, 2010	planning	medicine: it will become increasingly possible to		monitoring of disease	generic	and imaging
		analyse an individual for				
		certain				
		biomarkers to determine the				
		best course of				
		treatment				
UK technology	Policy	Personalised	10	Treatment and	Other -	Drugs (not
and innovation	planning	medicine		management of	generic	prophylactic
futures for the 2020s, 2010				symptoms and disease		vaccines)
UK technology	Policy	In-situ tissue	10	Treatment and	Other -	Regenerative
and innovation	planning	regeneration:		management of	generic	medicine
futures for the		Material is		symptoms and		
2020s, 2010		implanted directly		disease		
		in the body and				
		regenerates the tissue over time				
		as the material				
		degrades.				
UK technology	Policy	Tissue	10	Treatment and	Other -	Regenerative
and innovation	planning	engineering:		management of	generic	medicine
futures for the		Material can act		symptoms and disease		
2020s, 2010		as temporary scaffold for cell		disease		
		culture and tissue				
		growth in vitro				
UK technology	Policy	Micro-masonry	10	Treatment and	Other -	Regenerative
and innovation	planning	and 3D organ		management of	generic	medicine
futures for the 2020s, 2010		printing techniques		symptoms and disease		
UK technology	Policy	Brain Computer	10	Rehabilitation	Other -	Devices and
and innovation	planning	Interface			generic	biomaterials
futures for the						
2020s, 2010						
UK technology	Policy	Neuroprosthetics:	10	Rehabilitation	VI -	Devices and
and innovation futures for the	planning	the connection			nervous	biomaterials
2020s, 2010		can occur between any part				
20203, 2010		of the nervous				
		system (such as				
		peripheral nerves)				
		and a device.				

UK technology and innovation futures for the 2020s, 2010	Policy planning	Magnetoencephal ography (MEG): maps brain activity by recording the magnetic fields produced by electrical currents occurring in the brain	10	Diagnosis and monitoring of disease	VI - nervous	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	functional magnetic imaging (fMRI) – involves measuring changes in blood flow related to neural activity in the brain.	10	Diagnosis and monitoring of disease	VI - nervous	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	functional Near- Infrared Spectroscopy (fNIRS) for optical topography	10	Diagnosis and monitoring of disease	Other - generic	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	Electrocorticograp hy (EoCG), measure the electrical activity of the brain using electrodes which are implanted inside the skull, but outside the brain tissue.	10	Diagnosis and monitoring of disease	VI - nervous	Diagnostic tests and imaging
UK technology and innovation futures for the 2020s, 2010	Policy planning	Implanted brain chips for controlling computers	10	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
UK technology and innovation futures for the 2020s, 2010	Policy planning	Neural prosthetics replace lost limbs	5	Rehabilitation	XXI - screening, rehab	Devices and biomaterials
UK technology and innovation futures for the 2020s, 2010	Policy planning	Thought- controlled robots for personal healthcare	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	Medical equipment
UK technology and innovation futures for the 2020s, 2010	Policy planning	Thought- controlled wheelchairs	10	Rehabilitation	XXI - screening, rehab	Medical equipment

UK technology and innovation futures for the 2020s, 2010	Policy planning	ehealth: Examples include health information networks, electronic health records, telemedicine services, personal wearable and portable mobile devices, health portals and other tools that assist in health monitoring, diagnosis and treatment.	10	Supporting the provision of care and/or increasing service efficiency	Other - generic	IT systems, eHealth and mHealth
UK technology and innovation futures for the 2020s, 2010	Policy planning	Lab-on-a-chip technologies could also bring diagnostics down to a personal scale, where patients can test themselves and transmit data electronically for analysis and treatment.	10	Supporting patients receiving care (designed to be used by individuals)	Other - generic	IT systems, eHealth and mHealth
UK technology and innovation futures for the 2020s, 2010	Policy planning	Tailored Medicine	10	Treatment and management of symptoms and disease	Other - generic	Drugs (not prophylactic vaccines)
Technology foresight towards 2020_China	Policy planning	The anti-viral medicine with highly efficiency applies to clinical medicine widely	17	Treatment and management of symptoms and disease	I - infections	Drugs (not prophylactic vaccines)
Technology foresight towards 2020_China	Policy planning	standardized safe evaluation system which include the technology for monitoring and examination of trans-gene biology will be established;	17	Supporting the provision of care and/or increasing service efficiency	Other - generic	Organisational programmes